Hook & thesis
UiPath is the enterprise workflow and automation company that many investors have written off in 2026 after a volatile stretch. That’s precisely why it looks interesting here: the stock trades near $13 with a market capitalization of about $6.8 billion yet now generates positive earnings and meaningful free cash flow. The company’s agentic AI and orchestration positioning — the glue between large language models, enterprise data and process automation — gives UiPath a durable growth runway even if top-line growth is moderating.
My thesis is straightforward: buy UiPath at current levels because the valuation is reasonable for a software company that just turned profitable on an EPS basis, is producing free cash flow (~$363 million), and is deepening enterprise penetration (21% growth in million-dollar customers). Sentiment is weak, analyst estimates have been revised up recently, and technicals show the stock is basing after a sharp pullback. This trade idea lays out an actionable entry at $13.13, a protective stop at $10.00, and staged upside targets to capture both the re-rating and fundamental progress.
Why the market should care - business and fundamental driver
UiPath builds software that automates business processes across finance, healthcare, public sector, and telecoms. The company’s platform spans attended and unattended automation, AI agents, and workflow orchestration - essentially the plumbing that connects enterprise systems, data, and generative AI capabilities into reliable business outcomes (billing automation, claims processing, contact centers, etc.). In the current cycle, CIOs want to automate repetitive work and stitch AI into workflows; that puts UiPath squarely in the path of enterprise IT budgets.
Two fundamental drivers matter most: deeper enterprise penetration and better unit economics. The company reported a 21% increase in million-dollar customers to 387, which suggests stronger upsell and stickiness at the largest accounts. At the same time UiPath has moved to profitability; trailing EPS sits around $0.69 with a P/E near 19x on reported numbers, while free cash flow is a healthy $362.96 million. For a software business with scale, those are meaningful proof points that give valuation upside room even if revenue growth slows from prior peaks.
Support with the numbers
- Market cap: approximately $6.84 billion and an enterprise value near $6.08 billion.
- Profitability: EPS around $0.69 and a price-to-earnings near 19x (forward P/E metrics in the high-teens territory).
- Cash flow: free cash flow roughly $363 million, which supports reinvestment and de-risks capital needs.
- Customer momentum: million-dollar customer cohort rose 21% to 387, outpacing broader $100k+ ARR segment growth.
- Valuation multiples: EV/sales ~3.54 and EV/EBITDA ~21.1, reasonable relative to earlier high-growth software comps that traded well above these levels during expansion eras.
Valuation framing
UiPath trades at a P/E in the high-teens and EV/sales a little above 3.5x. That’s materially cheaper than the frothy multiples seen in the last software bull market and more attractive than many high-growth peers. Given the company’s move to positive EPS and strong free cash flow, a multiple re-rating back toward 20-25x on EPS or modest expansion in EV/sales could produce meaningful upside. Practically speaking, the stock doesn’t need to return to prior peak multiples to deliver solid returns — sustained revenue growth in the high single digits to low double-digits plus margin expansion driven by operating leverage would justify a $18 handle over the next 6-9 months.
Catalysts
- Continued expansion in million-dollar customers and higher ARR per account, which would show product-market fit at scale.
- Further analyst upgrades and upward EPS revisions; consensus EPS revision has already shown strength recently.
- Product announcements that demonstrate agentic AI and orchestration advantages versus competitors, which could accelerate large deal activity.
- Improving macro IT spend that translates into steadier enterprise software renewal and expansion behavior.
- Quarterly beats on revenue and margin that demonstrate sustainable profitability and cash generation.
Trade plan - actionable entry, stops and targets
Here is a pragmatic, horizon-specific plan:
| Action | Price | Horizon | Rationale |
|---|---|---|---|
| Entry | $13.13 | Short term (10 trading days) | Buy on a base breakout or stabilization above the $13 level; RSI is below neutral which limits immediate downside breadth. |
| Stop | $10.00 | Applies across all horizons | Protects capital below the recent range low and gives room for earnings season volatility. |
| Target 1 | $15.50 | Mid term (45 trading days) | Captures a move back toward the 50-day SMA and early multiple re-rating. |
| Target 2 | $18.00 | Long term (180 trading days) | Reflects combination of EPS growth and multiple expansion toward software peer averages. |
Horizon notes
Short term (10 trading days): Expect consolidation around $12.80-$13.50. Use this window to establish or add on weakness. Mid term (45 trading days): Look for re-rating as quarterly results and customer metrics flow through. Long term (180 trading days): This is the period where sustained FCF generation and enterprise adoption should show up in margins and multiple expansion.
Technicals & positioning
Technically the stock has pulled back from its 52-week high ($19.84) and sits below the 20- and 50-day SMAs ($13.68 and $14.53 respectively). Momentum indicators show some bearish pressure - MACD is negative and RSI sits around 43 - but the setup is characteristic of a base that can resolve to the upside if earnings and customer metrics continue to improve. Short interest remains elevated (roughly 100M+ shares recently), which can amplify moves both ways and increase volatility around catalysts.
Risks and counterarguments
There are clear reasons to be cautious. I list four material risks and then offer a counterargument to my own thesis:
- Growth deceleration. Revenue growth has slowed versus earlier peaks; the market values growth, and a prolonged slowdown would keep valuation compressed.
- Competition and displacement. Competitors like Pegasystems and ServiceNow are strong in workflow and low-code automation. Larger cloud vendors could bundle automation capabilities into existing platforms, pressuring pricing and deal sizes.
- Sentiment-driven volatility. The stock fell sharply in recent months and short activity is elevated; this increases the chance of outsized drawdowns around negative headlines or macro shocks.
- Execution risk on agentic AI productization. Integrating generative AI into robust, secure enterprise workflows is technically difficult. Any missteps (performance, security, or compliance issues) could slow enterprise adoption.
Counterargument: Even if growth slows further, UiPath’s move to positive EPS and sizable free cash flow insulates the business. That creates an asymmetry: downside is limited by cash generation and reasonable multiples, while upside comes from re-acceleration in large deals and margin expansion. In other words, improving profitability reduces existential risk that used to justify much larger discounts.
What would change my mind
I would downgrade the thesis if any of the following occur: a quarter of revenue decline or a meaningful miss on ARR growth; signs that million-dollar customer growth is plateauing (less than mid-single-digit growth year-over-year); or a clear loss of material enterprise deals to competitors resulting in visible churn. Conversely, sustained double-digit ARR growth acceleration, continued margin expansion and higher free cash flow conversion would strengthen the bull case and prompt adding to the position.
Conclusion
UiPath is an actionable long at current levels. The business sits at the intersection of automation and enterprise AI orchestration, is producing free cash flow, and shows improving profitability — all at a market cap of roughly $6.8 billion and valuation multiples that look reasonable for a profitable software company. The trade is not without risk: execution, competition and sentiment volatility are real. But with a $10 stop and staged targets at $15.50 and $18.00 across 10, 45 and 180 trading day horizons respectively, the risk-reward favors a buy for investors comfortable with software cyclicality and event-driven volatility.
Trade summary: Long PATH at $13.13. Stop $10.00. Targets $15.50 (mid-term) and $18.00 (long-term). Maintain position discipline and monitor customer metrics and quarterly results closely.